Homelife sciences

life sciences

$Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH$

Biotech

Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH

December 12, 2022

Biotech

100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)

December 12, 2022

Biotech

Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation

December 12, 2022

Biotech

Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 12, 2022

Biotech

CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition

December 11, 2022

Biotech

Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

December 11, 2022

Biotech

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

December 10, 2022

$Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma$

Biotech

Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

December 10, 2022

Biotech

Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting

December 10, 2022

Biotech

EIGR INVESTOR NEWS: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

December 9, 2022

« 1 … 13 14 15 16 17 … 557 »

SEARCH FOR AN ARTICLE

life sciences

Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH

100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)

Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation

Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition

Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting

EIGR INVESTOR NEWS: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

LATEST NEWS